10:37 AM EST - Immunovaccine Inc. : Announced that the UHN's Princess Margaret Cancer Centre will conduct a Phase 2 clinical trial to evaluate the use of a combination of immunotherapies from Immunovaccine and Merck. Immunovaccine Inc.
shares T.IMV are trading up $0.10 at $0.99.
